2023 European Society of Cardiology guidelines for the management of cardiovascular disease in patients with diabetes: Statement of endorsement by the NVVC
Publication date
2025-07
Authors
Martens, Fabrice M.A.C.
Visseren, Frank L.J.
Westerink, J.
Spee, Ruud F.
Saloua, El Messaoudi
Mosterd, Arend
Handoko, M L
Leening, Maarten J.G.
Römer, Tjeerd J.
Slootweg, Andries
Editors
Advisors
Supervisors
Document Type
Article
Metadata
Show full item recordCollections
License
cc_by
Abstract
The 2023 update of the European Society of Cardiology guidelines for the management of cardiovascular disease (CVD) in patients with diabetes are designed to guide prevention, early diagnosis, and management of CVD in patients with diabetes and provide recommendations on CVD risk stratification, as well as on screening. This article provides a summary of the key recommendations and a practical approach for cardiologists in the Netherlands to implement these guidelines in daily clinical practice by focusing on recommendations related to type 2 diabetes, including a step-by-step scheme for prescription of Sodium-Glucose Transport Protein 2 Inhibitors (SGLT2) inhibitors and Glucagon-like peptide‑1 (GLP-1) receptor agonists. These agents can be prescribed in addition to standard care, and independent of glucose control, target HbA1c, or obesity.
Keywords
Cardiovascular disease, Diabetes, GLP‑1 receptor agonists, SGLT2 inhibitors, Cardiology and Cardiovascular Medicine, Journal Article, Review
Citation
Martens, F M A C, Visseren, F L J, Westerink, J, Spee, R F, Saloua, E M, Mosterd, A, Handoko, L M, Leening, M J G, Römer, T J, Slootweg, A, van Bon, A C & Hemels, M E W 2025, '2023 European Society of Cardiology guidelines for the management of cardiovascular disease in patients with diabetes : Statement of endorsement by the NVVC', Netherlands Heart Journal, vol. 33, no. 7, pp. 216-225. https://doi.org/10.1007/s12471-025-01967-y